Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study.


Journal

Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 6 2 2019
medline: 31 1 2020
entrez: 6 2 2019
Statut: ppublish

Résumé

To explore individuals' experiences of daytime use of a day-and-night hybrid closed-loop system, their information and support needs, and their views about how future systems could be improved. Twenty-four adults, adolescents, and parents were interviewed before using a hybrid day-and-night closed-loop system and 3 months later, data were analyzed thematically. Participants praised the closed loop's ability to respond to high and low blood glucose in ways which extended beyond their own capabilities and to act as a safety net and mop up errors, such as when a mealtime bolus was forgotten or unplanned activity was undertaken. Participants also described feeling less burdened by diabetes as a consequence and more able to lead flexible, spontaneous lives. Contrary to their initial expectations, and after trust in the system had been established, most individuals wanted opportunities to collaborate with the closed loop to optimize its effectiveness. Such individuals expressed a need to communicate information, such as when routines changed or to indicate different intensities of physical activity. While individuals valued frequent contact with staff in the initial month of use, most felt that their long-term support needs would be no greater than when using an insulin pump. While participants reported substantial benefits to using the closed loop during the day, they also identified ways in which the technology could be refined and education and training tailored to optimize effective use. Our findings suggest that mainstreaming this technology will not necessarily lead to increased demands on clinical staff.

Identifiants

pubmed: 30720338
doi: 10.1089/dia.2018.0306
pmc: PMC6434584
doi:

Substances chimiques

Blood Glucose 0
Hypoglycemic Agents 0
Insulin 0

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-127

Subventions

Organisme : Department of Health
ID : 14/23/09
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100574/Z/12/Z
Pays : United Kingdom

Références

Diabetes Educ. 2017 Apr;43(2):223-232
pubmed: 28340542
Diabetes Technol Ther. 2017 Jul;19(7):410-416
pubmed: 28537437
J Diabetes Sci Technol. 2015 Oct 01;9(6):1217-26
pubmed: 26428933
Diabet Med. 2017 Feb;34(2):262-271
pubmed: 27696520
Lancet. 2018 Oct 13;392(10155):1321-1329
pubmed: 30292578
Pediatr Diabetes. 2016 Feb;17(1):28-35
pubmed: 25348683
Diabet Med. 2015 May;32(5):601-8
pubmed: 25615888
Diabetes Obes Metab. 2014 Nov;16(11):1174-8
pubmed: 24909206
J Diabetes Sci Technol. 2015 Jul;9(4):932-3
pubmed: 25852073
Diabetes Technol Ther. 2012 Oct;14(10):858-61
pubmed: 22856588
J Diabetes Sci Technol. 2010 May 01;4(3):596-602
pubmed: 20513325
J Health Psychol. 2020 Mar;25(4):429-438
pubmed: 28810490
BMJ. 1995 Jul 1;311(6996):42-5
pubmed: 7613329
Diabetes Care. 2017 Nov;40(11):1453-1461
pubmed: 28842523
Diabetes Technol Ther. 2016 Mar;18(3):115-7
pubmed: 26983025
J Diabetes Sci Technol. 2016 May 03;10(3):714-23
pubmed: 26589628
BMC Public Health. 2012 Aug 14;12:652
pubmed: 22891794
BMC Med. 2017 Jan 23;15(1):14
pubmed: 28114938
BMJ. 1995 Jul 22;311(6999):251-3
pubmed: 7627048
J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088
pubmed: 28367636
Diabetes Res Clin Pract. 2012 Nov;98(2):236-42
pubmed: 23084281
Diabet Med. 2019 Jun;36(6):753-760
pubmed: 30575114
BMJ Open Diabetes Res Care. 2014 Apr 16;2(1):e000025
pubmed: 25452866
Diabetes Res Clin Pract. 2014 Dec;106(3):443-50
pubmed: 25451897
Diabetes Technol Ther. 2017 Nov;19(11):660-674
pubmed: 28854339
Diabet Med. 2017 Oct;34(10):1461-1469
pubmed: 28631849
Diabetes Care. 2016 Dec;39(12):2158-2164
pubmed: 27852685
Diabet Med. 2015 Aug;32(8):1063-70
pubmed: 25472898
Lancet Diabetes Endocrinol. 2015 Jan;3(1):17-26
pubmed: 25434967
Diabetes Technol Ther. 2015 May;17(5):311-5
pubmed: 25629627
J Diabetes Sci Technol. 2015 May;9(3):609-18
pubmed: 25568144

Auteurs

Julia Lawton (J)

1 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.

Maxine Blackburn (M)

1 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.

David Rankin (D)

1 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.

Janet M Allen (JM)

2 Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
3 Department of Pediatrics, University of Cambridge, Cambridge, United Kingdom.

Fiona M Campbell (FM)

4 Leeds Children's Hospital, Leeds, United Kingdom.

Lalantha Leelarathna (L)

5 Manchester Diabetes Center, Manchester Academic Health Science Center, Manchester University NHS Foundation Trust, University of Manchester, Manchester, United Kingdom.

Martin Tauschmann (M)

2 Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
3 Department of Pediatrics, University of Cambridge, Cambridge, United Kingdom.

Hood Thabit (H)

5 Manchester Diabetes Center, Manchester Academic Health Science Center, Manchester University NHS Foundation Trust, University of Manchester, Manchester, United Kingdom.

Malgorzata E Wilinska (ME)

2 Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
3 Department of Pediatrics, University of Cambridge, Cambridge, United Kingdom.

Daniela Elleri (D)

6 Royal Hospital for Sick Children, Edinburgh, United Kingdom.

Roman Hovorka (R)

2 Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
3 Department of Pediatrics, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH